On Thursday, Viking Therapeutics (NASDAQ:VKTX) received a favorable initiation of coverage from Jefferies, with a Buy rating and a price target set at $110.00. The... Biotech firm Viking ...
1. Cloudera, Inc. (NYSE:CLDR) broke out of a platform on Wednesday that has been forming for 7 or 8 weeks. It popped 74 cents, or 8 1/2%, to 9.39, just 4 cents off the session ...
The stock also underperformed the broader Medical sector and the S&P 500 during this timeframe, as shown in the chart below. VKTX’s shares are currently trading below the 50 and 200-day moving ...
The chart below shows the one year performance of VKTX shares: Looking at the chart above, VKTX's low point in its 52 week range is $20.28 per share, with $99.41 as the 52 week high point — that ...
Shares of Viking Therapeutics VKTX have lost nearly 22% in the past six months, significantly underperforming the industry’s 5.3% decline. The stock also underperformed the broader Medical sector and ...